4536
Fiscal year ends March Quarters are offset from the calendar — Q1 is Apr–Jun

Santen Pharmaceutical Co., Ltd. is a pharmaceutical company focused on the research, development, manufacturing, and sale of ophthalmic drugs and medical devices. The company operates as a single segment, offering prescription and over-the-counter eye medications, as well as advanced vision science products. Its business activities span Japan, China, Asia, Europe, the Middle East, Africa, and the Americas. Key subsidiaries include Santen Inc., Eyevance Pharmaceuticals, Advanced Vision Science, and InnFocus. The company serves patients and healthcare providers globally through a network of regional entities such as Santen Holdings EU B.V., Santen India Private Limited, and Santen Pharmaceutical Asia Pte. Ltd.

Summarised from the annual report, fiscal year ended Mar 2026

Industry Drug Manufacturers - General Homepage santen.com/en
Sector Healthcare IR page santen.com/en
Tags
ophthalmology, eye care, prescription drugs, over-the-counter drugs, medical devices, vision science, Santen Inc., Eyevance Pharmaceuticals, Advanced Vision Science, InnFocus, Santen Holdings EU B.V., Santen India Private Limited, Santen Pharmaceutical Asia Pte. Ltd., Santen Canada Inc., Santen Ventures, Santen Oy, Santen S.A.S., Santen GmbH, Santen SAS, Santen Italy S.r.l., Santen UK Limited, Santen Pharmaceutical Spain S.L., SANTEN LIMITED LIABILITY COMPANY, Santen Pharmaceutical Vietnam Co. Ltd., SANTEN (THAILAND) CO. LTD., SANTEN PHILIPPINES INC., SANTEN PHARMA MALAYSIA SDN. BHD., Santen Holdings U.S. Inc., Eyevance Pharmaceuticals Holdings Inc., Eyevance Pharmaceuticals LLC, Santen Pharmaceutical Co. Ltd., Santen Pharmaceutical (China) Co. Ltd., Santen Pharmaceutical (Suzhou) Co. Ltd., Chongqing Santen Kerui Pharmaceutical Co. Ltd., Santen Pharmaceutical (Hong Kong) Co. Ltd., Santen Pharmaceutical Korea Co. Ltd., Santen Pharmaceutical Taiwan Co. Ltd.
Press page santen.com/ja/news

Metrics

Valuation  
Market cap ¥ 562.116B
Market cap (USD) $ 3.526B
P/E 14.49
PEG —
P/BV 1.85
P/S 1.89
P/OCF 11.32
P/FCF 15.61
Dividend yield 2.2%
Turnover / mcap —
Returns  
ROE 12.9%
ROI 12.6%
ROIC 12.8%
Profit margin 12.8%
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock Yes
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 42
Quality score 22.2%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 291.624B 300.004B 301.965B 279.037B 266.257B 249.605B 241.555B 234.026B 224.942B 199.096B 195.291B 161.881B 148.663B 119.066B
Net profit 37.369B 36.256B 26.642B -14.948B 27.218B 6.83B 23.618B 31.954B 35.247B 23.061B 53.373B 22.57B 17.109B 16.52B
Free cash flow 29.234B 49.909B 61.962B 12.559B 10.202B 15.004B 30.719B 24.561B — — — — — —

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 1.789K 1.416K 1.538K 1.225K 1.225K 1.524K 1.859K 1.65K 1.716K 1.614K 1.69K 1.752K 915.92 4.447K
Price performance 12m 0.26 -0.08 0.26 0 -0.2 -0.18 0.13 -0.04 0.06 -0.05 -0.04 0.91 -0.79 —

Filed figures

Figure Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Balance sheet detail
Trade receivables (JPY) — 78.7B 84.6B 87B 96B 99.6B 107B 90.5B 71.8B 71.8B
↳ YoY growth +7.6% +2.8% +10.3% +3.7% +7.6% -15.5% -20.7% >-0.01%
↳ 5y CAGR +6.4% +1.4% -3.8% -5.7%
Cash and deposits (JPY) 52.3B 69.3B 70.8B 91.4B 62.9B 83B 57.9B 94.6B 93B 80.9B
Intangible assets (JPY) — 134B 131B 120B 113B 130B 96.3B 83.8B 75.5B 71.7B
Cash flow detail
Operating cash flow (JPY) 10.8B 42.8B 32.9B 39.9B 38.8B 46B 37.1B 72.6B 60.9B 43.5B
Purchases of property, plant and equipment (JPY) — -3.98B -5.47B -5.82B -4.14B -17.3B -17.3B -9.32B -6.66B -6.84B
Purchases of intangible assets (JPY) — -5.95B -2.86B -3.4B -19.7B -18.5B -7.31B -1.37B -4.36B -7.42B
Change in receivables (cash effect) (JPY) — -7.12B -6.3B -3.05B -7.51B -1.97B -6.44B 18.4B 18.5B 2.67B
Change in inventories (cash effect) (JPY) — -1.44B -5B -981M -4.59B 5.38B -1.14B -1.37B -8.38B -10B
Change in payables (cash effect) (JPY) — 5.7B 2.45B 717M 4.95B 2.49B 3.69B -2.38B -4.41B -4.44B
Dividends paid (cash effect) (JPY) — -10.6B -10.6B -10.4B -11.2B -12B -12.6B -11.9B -12.1B -12.6B
Share buybacks (cash effect) (JPY) — -1M -14.1B -22M — -12M -26B -17B -37.9B -32.8B
Interest paid (cash effect) (JPY) — -27M -8M -190M -159M -240M -465M -830M -1.09B -1.26B
Operating cash flow before change in receivables (JPY) — 50B 39.2B 43B 46.3B 48B 43.6B 54.3B 42.4B 40.8B
Free cash flow (OCF - PPE - intangibles) (JPY) — 32.9B 24.6B 30.7B 15B 10.2B 12.6B 62B 49.9B 29.2B
Income detail
Research and development expense (JPY) — 24.4B 23.8B 23.3B 24.1B 26.4B 28.3B 25.4B 24.1B 26.2B
↳ 5y CAGR +3.0% +1.3% +0.7% +1.7%
Total comprehensive income (JPY) — 40.7B 29.5B 20.2B 15.4B 38.6B -5.7B 40B 29B 55.5B
Comprehensive income to owners (JPY) 15.9B 40.6B 29.5B 22.2B 15.6B 38.7B -5.66B 40B 29.3B 55.4B
Reported Jun 23, 2017 Jun 25, 2019 Jun 25, 2019 Jun 24, 2020 Jun 25, 2021 Jun 27, 2023 Jun 27, 2023 Jun 25, 2024 Jun 23, 2025 Jun 18, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

Santen Pharmaceutical Co., Ltd. (ticker 4536), listed in Japan.

ETFs Holding Santen Pharmaceutical Co., Ltd.

ETF Weight in ETF Shares Market value As of
JPAN 0.79% 6,000 $ 78.745K Jun 30, 2026
AVDS 0.12% 32,700 $ 425.458K Nov 16, 2026
DFIS 0.06% 283,700 $ 3.551M Nov 12, 2026
AVSD 0.04% 11,400 $ 148.325K Nov 16, 2026
DFIC 0.04% 460,700 $ 5.767M Nov 12, 2026
DFSI 0.03% 26,100 $ 326.699K Nov 12, 2026
DXIV 0.03% 5,100 $ 63.838K Nov 12, 2026
DFAX 0.02% 218,800 $ 2.739M Nov 12, 2026
DFAI 0.02% 285,895 $ 3.579M Nov 12, 2026
AVDE 0.00% 18,500 $ 240.702K Nov 16, 2026